亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

O-8 Atezolizumab + bevacizumab vs sorafenib for unresectable hepatocellular carcinoma: Results from older adults enrolled in IMbrave150

医学 索拉非尼 阿替唑单抗 内科学 贝伐单抗 肝细胞癌 肿瘤科 总体生存率 生活质量(医疗保健) 无进展生存期 扩展访问 不利影响 伦瓦提尼 胃肠病学 癌症 化疗 无容量 免疫疗法 护理部
作者
D. Li,Han Chong Toh,Philippe Merle,Kaoru Tsuchiya,Sairy Hernandez,Hui Shao,Sohail Mulla,Beiying Ding,Masatoshi Kudo
出处
期刊:Annals of Oncology [Elsevier BV]
卷期号:31: 234-234 被引量:11
标识
DOI:10.1016/j.annonc.2020.04.061
摘要

Data regarding the efficacy and safety of systemic therapies in older adults with hepatocellular carcinoma (HCC) are limited. In the phase III IMbrave150 trial, atezolizumab + bevacizumab was associated with statistically significant and clinically meaningful improvements in overall survival (OS; HR, 0.58; 95% CI: 0.42, 0.79) and progression-free survival (PFS; HR, 0.59; 95% CI: 0.47, 0.76) as well as clinically meaningful delays in deterioration of patient-reported functioning and quality of life (QoL) vs sorafenib in patients with unresectable HCC who had not received prior systemic therapy (Cheng, ESMO Asia, 2019). Here, we report exploratory subgroup analyses of the efficacy, safety and patient-reported outcome (PRO) results for older adults enrolled in IMbrave150. IMbrave150 randomized 501 systemic treatment (tx)–naïve patients with unresectable HCC. Patients were randomized 2:1 to receive either atezolizumab 1200 mg IV q3w + bevacizumab 15 mg/kg IV q3w or sorafenib 400 mg BID until unacceptable toxicity or loss of clinical benefit per investigator. Co-primary endpoints were OS and PFS by independent review facility (IRF)-assessed RECIST 1.1. Objective response rate (ORR) per IRF-RECIST 1.1 and time to deterioration (TTD) in patient-reported physical functioning, role functioning and QoL per the EORTC QLQ-C30 questionnaire were pre-specified secondary endpoints. The exploratory older adult subgroup was defined to include those aged ≥ 65 years. In IMbrave150, 161 (48%) patients enrolled in the atezolizumab + bevacizumab arm and 91 (55%) in the sorafenib arm were aged ≥ 65 years. In these patients, the median OS was not reached with atezolizumab + bevacizumab vs 14.9 months with sorafenib (HR, 0.58; 95% CI: 0.36, 0.92). The median PFS was 7.7 months with atezolizumab + bevacizumab vs 4.8 months with sorafenib (HR, 0.63; 95% CI: 0.45, 0.89). ORRs were 26% with atezolizumab + bevacizumab vs 13% with sorafenib, with 7 and 0 patients achieving complete responses, respectively. TTD in physical functioning (HR, 0.48; 95% CI: 0.32, 0.73), role functioning (HR, 0.61; 95% CI: 0.40, 0.91) and QoL (HR, 0.71; 95% CI: 0.47, 1.07) were longer for patients receiving atezolizumab + bevacizumab vs sorafenib. In the atezolizumab + bevacizumab arm, 62 of 158 (39%) treated patients aged ≥ 65 years experienced a grade 3-4 treatment-related AE (TRAE) and 4 (3%) patients experienced a grade 5 TRAE, whereas 55 of 171 (32%) treated patients aged < 65 years experienced a grade 3-4 TRAE and 1 (1%) patient experienced a grade 5 TRAE. Exploratory analyses were also conducted with the subgroup of patients aged ≥ 70 years, showing similar results for efficacy, safety and PROs. Similar to the IMbrave150 ITT population, older adults with previously untreated, unresectable HCC derived a clinically meaningful benefit from atezolizumab + bevacizumab vs sorafenib. Additionally, treatment with atezolizumab + bevacizumab showed a delay in deterioration in patient-reported functioning and QoL vs sorafenib. Safety of atezolizumab + bevacizumab in adults ≥ 65 years old is generally consistent with the safety in younger patients, with no added risks or toxicities.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
hgl完成签到,获得积分10
21秒前
30秒前
科研通AI2S应助科研通管家采纳,获得10
38秒前
38秒前
华仔应助精明晓刚采纳,获得10
59秒前
1分钟前
1分钟前
精明晓刚发布了新的文献求助10
1分钟前
糖伯虎完成签到 ,获得积分10
2分钟前
在水一方应助科研通管家采纳,获得10
2分钟前
光合作用完成签到,获得积分10
2分钟前
3分钟前
精明晓刚发布了新的文献求助10
3分钟前
精明晓刚完成签到,获得积分10
3分钟前
4分钟前
搜集达人应助kangkang采纳,获得10
4分钟前
英姑应助科研通管家采纳,获得10
4分钟前
kangkang完成签到,获得积分20
4分钟前
5分钟前
刘紫媛发布了新的文献求助10
5分钟前
故意的冰淇淋完成签到 ,获得积分10
5分钟前
刘紫媛完成签到,获得积分20
5分钟前
Lucas应助Dave采纳,获得10
5分钟前
刘紫媛关注了科研通微信公众号
5分钟前
6分钟前
Akitten发布了新的文献求助10
6分钟前
草木完成签到 ,获得积分20
6分钟前
完美世界应助科研通管家采纳,获得10
6分钟前
领导范儿应助科研通管家采纳,获得10
6分钟前
Orange应助Boren采纳,获得10
7分钟前
7分钟前
Boren发布了新的文献求助10
7分钟前
大个应助Boren采纳,获得10
7分钟前
Raunio完成签到,获得积分10
7分钟前
Akitten发布了新的文献求助10
8分钟前
完美世界应助lhy采纳,获得10
8分钟前
科研通AI2S应助科研通管家采纳,获得10
8分钟前
8分钟前
8分钟前
8分钟前
高分求助中
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3990332
求助须知:如何正确求助?哪些是违规求助? 3532146
关于积分的说明 11256483
捐赠科研通 3271042
什么是DOI,文献DOI怎么找? 1805207
邀请新用户注册赠送积分活动 882302
科研通“疑难数据库(出版商)”最低求助积分说明 809234